The injectable iron preparation Фер-Ромфарм is used for focused therapeutic support, targeting severe iron deficiency and the debilitating symptom patterns it creates. This medication is typically applied when patients experience an intolerance to oral iron or when oral administration is considered unsuitable.

Symptom Management and Therapeutic Focus

This therapy is relevant in conditions characterized by periods of heightened symptoms of anemia, and is used to help manage severe iron-deficiency anemia in situations where iron stores are critically depleted. Фер-Ромфарм supports the management of symptom clusters that interfere with daily functioning, primarily profound fatigue, systemic weakness, and reduced endurance. Common clinical scenarios for its application include managing iron deficiency associated with malabsorption syndromes, chronic kidney disease, and other conditions requiring substantial iron replenishment.

“This therapy contributes to easing the overall symptom load, assisting with maintaining functional stability during symptomatic phases.”

Quick Fact: Relief for Systemic Fatigue
Symptom Cluster	Profound weakness and reduced endurance
Context of Use	When oral iron failure necessitates replacement
Overall Support	Contributes to maintaining functional stability

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications for Фер-Ромфарм (Iron Dextran)

The official eligibility profile for Фер-Ромфарм (Iron Dextran) is determined by regulatory criteria that define approved populations and strict prohibitions. The medicine is intended only for patients with documented iron deficiency who cannot tolerate or adequately respond to oral iron.

Eligibility Status	Defined Populations (Regulatory Statements)
Contraindicated (Must Not Use)	Patients with a known hypersensitivity to parenteral iron products, confirmed iron overload (e.g., haemochromatosis), non-iron deficiency anemia (e.g., haemolytic anemia), decompensated liver cirrhosis, or acute infectious kidney disease.
Allowed Under Standard Use	Adult patients and pediatric patients ge 4 months of age who meet the criteria for documented iron deficiency and oral iron failure.
Restricted or Conditional Use	Infants under 4 months of age are not recommended for treatment. Caution is required for patients with serious impairment of liver function and those with a history of severe allergies, asthma, or inflammatory conditions (e.g., rheumatoid arthritis).

Pregnancy and Lactation Eligibility Status:

Use during pregnancy, especially the second and third trimesters, must be strictly assessed, as official warnings note that severe maternal adverse reactions may cause fetal bradycardia. Caution is also advised when administering the medicine to nursing mothers.

Interactions with other medicines and products

The interaction profile for Фер-Ромфарм, an injectable iron preparation, is defined by specific procedural restrictions and pharmacodynamic considerations documented in regulatory labeling, primarily due to its intravenous administration route and chemical nature.

---

Prohibited Co-Administration

Фер-Ромфарм must not be mixed with any other medicinal products or solutions in the same infusion container or line, including Total Parenteral Nutrition (TPN). This restriction is a chemical incompatibility rule aimed at preventing instability. The co-administration with Iron Chelating Agents is also restricted due to the contradictory therapeutic goals of iron replenishment versus iron removal.

---

Pharmacodynamic and Diagnostic Interference

Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Captopril, Enalapril) is documented as potentially increasing the risk for hypersensitivity or anaphylactic-type reactions.

The medicine is subject to administration-timing restrictions concerning specific diagnostic procedures. Its presence can interfere with scans using Technetium-labeled bone seeking agents ( ^99mTc agents), potentially leading to inaccurate results, such as reduced bony uptake of the radioisotope.

Furthermore, the administration is known to affect the reliability of certain laboratory tests. It may cause falsely elevated serum bilirubin values, falsely decreased serum calcium values, and can render colorimetric serum iron determinations meaningless for up to three weeks after administration. No clinically relevant pharmacokinetic or food/alcohol interactions are documented for the injectable solution.

Targeting the Cellular Antioxidant Defense System

Фер-Ромфарм initiates its action by functionally disrupting the cell's primary defense mechanism against lipid peroxidation. The drug acts as a functional inhibitor by targeting and depleting the coenzyme Reduced Glutathione (GSH). GSH is critical for the activity of Glutathione Peroxidase 4 (GPX4), the enzyme responsible for reducing toxic lipid hydroperoxides to less reactive lipid alcohols.

---

Mechanism: Triggering Lipid Oxidative Catastrophe

The depletion of GSH immediately impairs the protective function of GPX4. This enzymatic failure leads to an uncontrolled, rapid accumulation of toxic lipid peroxides within cell membranes, driving the cell toward a state of fatal oxidative stress. This initiation of a cascading biochemical failure defines the drug’s characteristic physiological effect profile.

---

Result: Regulated Cell Destruction via Ferroptosis

The overwhelming oxidative damage and subsequent membrane instability consequently initiates a distinct form of regulated necrotic cell death known as Ferroptosis. This resulting physiological consequence involves the regulated destruction and subsequent elimination of the target cells.

How to Use Фер-Ромфарм

Фер-Ромфарм is an injectable iron preparation administered by a healthcare professional in a medical setting. The official instructions for its use detail the required route, calculated dosing, and procedural steps to ensure proper administration.

Administration Scope and Route

This medicine is administered via intravenous (IV) injection or infusion or through deep intramuscular (IM) injection. Oral iron preparations must be discontinued before treatment begins.

Dosing and Scheduling

The total dose required for iron replacement is not a fixed amount; it is precisely calculated using a weight-based formula that factors in the patient's current hemoglobin and target hemoglobin levels.

Administration Detail	Official Guideline
Maximum Daily Dose	100 mg elemental iron (2 mL) for most adults and children greater than or equal to 10 kg.
Pediatric Dosing	Approved for children 4 months of age and older. Maximum daily doses are adjusted by weight, with lower limits for infants under 10 kg.
Treatment Duration	Therapy continues until the patient's hemoglobin is within the normal range and iron stores are fully replete.

Procedural Instructions

Administration requires specific steps:

1. A 0.5 mL (25 mg) test dose is administered first.
2. The patient must be observed for a minimum of one hour following the test dose before the main therapeutic dose is given.
3. The IV injection rate must be controlled, not exceeding 50 mg (1 mL) per minute.
4. For IM use, the Z-track technique is required for deep injection into the muscle to contain the medication.
5. If dilution is necessary for IV infusion, only 0.9% sodium chloride or 5% glucose solution is permitted; the solution must not be mixed with other medications.

Фер-Ромфарм: Recent Clinical Evidence

Research Evidence for Severe Iron-Deficiency Anemia (IDA)

Research examining this intravenous iron preparation included Randomized Controlled Trials (RCTs) that compared the iron injection against oral iron preparations and, in some cases, against other types of intravenous iron products. These studies focused on adults whose clinical status indicated a need for intravenous delivery, such as those with an intolerance to oral preparations or impaired iron absorption. Researchers examined blood parameters, including Hemoglobin (Hb) concentration, Serum Ferritin, and Transferrin Saturation (TSAT). Research highlights changes measured during the study period, where trials described patterns in which iron status markers were observed at a specific time point in the intravenous groups relative to the oral groups. Research also monitored symptoms like profound fatigue and weakness in the observed populations.

---

Studies for Anemia Management in Chronic Kidney Disease (CKD)

The evidence base for using this medicine in CKD often comes from prospective and retrospective observational studies, covering both dialysis and non-dialysis patients. Because iron deficiency in CKD is managed with concurrent treatments, research examined temporary physiological imbalance within a broader therapeutic plan. In these settings, studies monitored Hemoglobin levels, iron status markers (ferritin/TSAT), and tracked the necessary dose of Erythropoiesis-Stimulating Agents (ESAs). Studies described patterns where iron status and blood concentrations were observed relative to baseline following the medicine's administration.

---

Duration of Follow-up and Long-Term Data

The evidence derived from trials exploring short-term symptom changes typically involves follow-up durations ranging from four to six weeks. This provides insight into initial changes in blood and iron markers. However, long-term effects are not fully established. There is limited information for long-term outcomes, meaning that the durability of the observed iron replenishment over multiple years is not well characterized in large studies.

---

Evidence in Specific Patient Groups

Research has explored the use of this intravenous iron preparation in certain special populations. Studies monitored its administration in pregnant women during the second and third trimesters. The medicine was also evaluated in pediatric patients over certain body weights. The research also examined its application in patient groups where patients met the criteria for inadequate response to oral iron or were unable to use it.

---

Research Gaps and Uncertainties

Comparative evidence is lacking for a direct, head-to-head comparison of this specific formulation against all newer intravenous iron products, particularly in large, long-term trials. Additionally, data on the specific contribution of the iron complex in CKD patients can be uncertain, as research is often integrated with concurrent ESA therapy. Research exploring effects on very long-term health outcomes is limited. Findings describe group patterns, not personal outcomes.

Common questions about Фер-Ромфарм (FAQ)

Q: What is the maximum dose that can be given?

Official information states that the total iron replacement dose is not a fixed amount. Instead, it is precisely calculated by your healthcare provider using a formula that considers your body weight and your current and target hemoglobin levels. The total replacement dose is determined by the healthcare provider based on the patient's individual treatment plan.

---

Q: Can I drive or operate machinery after receiving the injection?

Regulatory documents indicate that this medicine can sometimes cause adverse reactions such as dizziness or headache. Patients are typically advised to be observed for a period after administration. Official information indicates that caution is necessary when driving or operating machinery if side effects such as dizziness or headache occur.

---

Q: What is the Z-track technique mentioned for IM injection?

The Z-track technique is a specific procedural requirement for deep intramuscular (IM) injection of this medicine. According to official administration instructions, this method is used to seal the medication deep within the muscle tissue. This method is intended to prevent the medication from leaking into the subcutaneous tissue, which may reduce the risk of pain or skin discoloration at the injection site.

---

Q: What should I do if I miss an appointment for my scheduled dose?

Official patient instructions recommend that if an appointment for a scheduled injection is missed, the patient should contact their healthcare provider as soon as possible to discuss rescheduling. This helps ensure that the treatment plan is followed as intended.

---

Q: What is the half-life of the iron or the dextran complex?

According to the official product information, the half-life of the iron dextran complex circulating in the blood of iron-deficient individuals typically ranges from approximately 5 hours to over 20 hours. The half-life refers to the time it takes for the concentration of the compound to be reduced by half in the bloodstream.

---

Q: Are there any dietary restrictions I need to follow while on this treatment?

Official information generally indicates that there are no clinically relevant food or alcohol interactions documented for this injectable solution. Patients are generally advised to continue their normal diet unless otherwise instructed by a healthcare professional.

---

Q: What is the difference between this and oral iron pills?

This medicine, as an injectable iron preparation, is a rapid and concentrated way to deliver iron directly into the body. Official use is reserved for patients with documented severe iron deficiency who have conditions that prevent them from absorbing oral iron pills effectively or who have not been able to tolerate them.

Official Storage and Disposal Requirements

Regulatory documentation defines strict conditions for storing and handling Фер-Ромфарм (Fer-Rompharm), an iron solution for injection, to maintain its stability.

Requirement Type	Official Instructions
Temperature Range	Store the medicinal product at a temperature between 2 °C and 25 °C.
Handling & Stability	The ampoules must be visually inspected for sediment and damage prior to use. The solution is for single-use and must be administered immediately after the ampoule is opened.
Protection	Store in a location protected from light.
Disposal	Disposal of unused or expired product should follow local pharmaceutical waste regulations. No specific hazardous waste classification is documented in the available regulatory text.

These guidelines ensure the product's integrity and are not to be confused with general medical advice or administration instructions.